modelVinorelbine_1

Diagram of Vinorelbine_1

Extends from Pharmacolibrary.Drugs.ATC.L.L01CA04_1.

Information

name:Vinorelbine_1
ATC code:L01CA04_1
route:oral
compartments:2
dosage:60mg
volume of distribution:5.7L
clearance:0.47L/h/kg
other parameters in model implementation

Vinorelbine is a semi-synthetic vinca alkaloid antineoplastic agent primarily used for treatment of non-small cell lung cancer and metastatic breast cancer.

Pharmacokinetics

Oral vinorelbine pharmacokinetics in adult cancer patients; values based on clinical studies with oral administration. Bioavailability is less than intravenous.

References

  1. Pétain, A, et al., & Ferré, P (2019). Effect of ethnicity on vinorelbine pharmacokinetics: a population pharmacokinetics analysis. Cancer chemotherapy and pharmacology 84(2) 373–382. DOI:10.1007/s00280-019-03872-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31134323

  2. Hamimed, M, et al., & Leblond, P (2022). Pharmacokinetics of oral vinorelbine in French children with recurrent or progressive primary low-grade glioma. British journal of clinical pharmacology 88(5) 2096–2117. DOI:10.1111/bcp.15131 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34709655

  3. Hamimed, M, et al., & Ciccolini, J (2022). Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model-based population pharmacokinetic analysis. Cancer chemotherapy and pharmacology 90(1) 29–44. DOI:10.1007/s00280-022-04446-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/35751658

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)